All In Biotech

Free tool

FAERS Monitor: Rowasa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019618 or its brand name (Rowasa, Mesalamine). Reports on generic versions are filed under their own applications.

Reports

28,157

Serious

24,946

89% of reports

Hospitalization

9,525

Death reported

1,988

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use6,489
  • colitis ulcerative4,631
  • drug ineffective4,453
  • condition aggravated3,401
  • diarrhoea2,667
  • haematochezia2,486
  • fatigue2,255
  • abdominal pain2,185
  • weight decreased1,956
  • headache1,910
  • nausea1,884
  • pyrexia1,834
  • frequent bowel movements1,817
  • intentional product use issue1,681
  • inappropriate schedule of product administration1,664

Reports by year received

View as table
YearReports
2004126
2005167
2006120
2007167
2008581
2009136
2010281
2011713
2012628
2013180
2014226
2015284
2016338
2017372
2018596
2019736
20201,165
20212,427
20224,173
20234,308
20244,045
20253,998
20262,389

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
colitis ulcerativeSignal4,63186.283.8350,340
frequent bowel movementsSignal1,81753.851.487,876
haematocheziaSignal2,48635.233.979,016
intentional product use issueSignal1,68114.613.920,952
condition aggravatedSignal3,4018.48.222,369
abdominal painSignal2,1857.16.811,407
inappropriate schedule of product administrationSignal1,6647.06.68,468
off label useSignal6,4895.65.525,192
weight decreasedSignal1,9565.35.06,794
pyrexiaSignal1,8344.03.84,127
diarrhoeaSignal2,6673.13.03,883
drug ineffectiveSignal4,4532.52.54,375
headacheSignal1,9102.32.21,408
fatigueSignal2,2552.22.11,466
nausea1,8841.81.7667

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.